Alnylam Pharmaceuticals
ALNY
#634
Rank
โ‚ฌ30.38 B
Marketcap
235,60ย โ‚ฌ
Share price
-0.80%
Change (1 day)
57.15%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : โ‚ฌ3.98 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are โ‚ฌ3.98 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚ฌ3.66 B6.1%
2022-12-31โ‚ฌ3.45 B28.02%
2021-12-31โ‚ฌ2.69 B38.78%
2020-12-31โ‚ฌ1.94 B127.66%
2019-12-31โ‚ฌ0.85 B257.99%
2018-12-31โ‚ฌ0.23 B25.34%
2017-12-31โ‚ฌ0.19 B-41.58%
2016-12-31โ‚ฌ0.32 B192.39%
2015-12-31โ‚ฌ0.11 B-5.48%
2014-12-31โ‚ฌ0.11 B8.37%
2013-12-31โ‚ฌ0.10 B-6.27%
2012-12-31โ‚ฌ0.11 B-8.08%
2011-12-31โ‚ฌ0.12 B-28.57%
2010-12-31โ‚ฌ0.17 B-16.57%
2009-12-31โ‚ฌ0.21 B-16.02%
2008-12-31โ‚ฌ0.25 B24.98%
2007-12-31โ‚ฌ0.20 B585.65%
2006-12-31โ‚ฌ29.42 M-4.67%
2005-12-31โ‚ฌ30.87 M109.75%
2004-12-31โ‚ฌ14.71 M-70.06%
2003-12-31โ‚ฌ49.15 M147.57%
2002-12-31โ‚ฌ19.85 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚ฌ0.52 B-86.94%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ7.74 B 94.50%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ2.27 B-42.99%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.55 B-85.99%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ5.66 M-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ57.35 B 1,339.91%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚ฌ58.08 B 1,358.14%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ33.76 B 747.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel